Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026)
Perrigo (PRGO) posted quarterly Other Non-Current Liabilities of $712.3 million for Q1 2026, up 31.54% year-over-year from $541.5 million in Q1 2025, and down 12.53% quarter-over-quarter from $814.3 million in Q4 2025.
Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Other Non-Current Liabilities for 14 consecutive years, with $712.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 31.54% year-over-year to $712.3 million; the TTM figure through Mar 2026 stood at $712.3 million (up 31.54% YoY), while the FY2025 annual figure was $814.3 million, up 63.12% from the prior year.
- Other Non-Current Liabilities retreated to $712.3 million in Q1 2026 per PRGO's latest filing, from $814.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $814.3 million in Q4 2025 and bottomed at $499.2 million in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $614.7 million across 5 years, with a median of $613.9 million in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities decreased 18.72% — and 2025, when it soared 63.12%.
- Perrigo's Other Non-Current Liabilities stood at $623.0 million in 2022, then decreased by 10.14% to $559.8 million in 2023, then fell by 10.83% to $499.2 million in 2024, then jumped by 63.12% to $814.3 million in 2025, then dropped by 12.53% to $712.3 million in 2026.
- Business Quant data shows PRGO's Other Non-Current Liabilities at $712.3 million in Q1 2026, $814.3 million in Q4 2025, and $689.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Perrigo | 1.98 Bn | 1.58 Bn | 313.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 608.80 Mn |
| Mar 28, 2026 | 712.30 Mn |
| Dec 31, 2025 | 814.30 Mn |
| Sep 27, 2025 | 689.70 Mn |
| Jun 28, 2025 | 673.40 Mn |
| Mar 29, 2025 | 541.50 Mn |
| Dec 31, 2024 | 499.20 Mn |
| Sep 28, 2024 | 660.30 Mn |
| Jun 29, 2024 | 535.40 Mn |
| Mar 30, 2024 | 526.20 Mn |
| Dec 31, 2023 | 559.80 Mn |
| Sep 30, 2023 | 613.90 Mn |
| Jul 1, 2023 | 658.70 Mn |
| Apr 1, 2023 | 637.60 Mn |
| Dec 31, 2022 | 623.00 Mn |
| Oct 1, 2022 | 573.20 Mn |
| Jul 2, 2022 | 577.00 Mn |
| Apr 2, 2022 | 554.20 Mn |
| Dec 31, 2021 | 530.10 Mn |
| Oct 2, 2021 | 565.80 Mn |